Jasper Therapeutics (JSPR) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Jasper Therapeutics (JSPR) has outperformed NewcelX (NCEL) over the past year, losing 76.7% versus a loss of 83.3%. Over five years, JSPR leads with a -99.7% price change compared with -99.7% for NCEL. Jasper Therapeutics is the larger company by market cap ($18.6 million vs $18.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JSPR | NCEL |
|---|---|---|
| Share price | $0.56 | $3.11 |
| Market cap | $18.63M | $17.96M |
| 1-day change | -1.70% | +2.47% |
| YTD return | -69.40% | +63.68% |
| 1-year return | -76.67% | -83.32% |
| 5-year return | -99.66% | -99.68% |
| P/E ratio (TTM) | — | 5.98 |
| EPS (TTM) | $-1.04 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.69 | $18.60 |
| 52-week low | $0.315 | $1.83 |
| Distance from 52-week high | -79.18% | -83.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +3471.43% | +639.55% |
| Average volume | 1.37M | 10.28K |
| Shares outstanding | 33.27M | 5.78M |
| Employees | — | 9 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Healthcare · Biotechnology
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Healthcare · Biotechnology · 9 employees
JSPR vs NCEL FAQ
Which is bigger, Jasper Therapeutics or NewcelX?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $18.63M compared with $17.96M for NewcelX (NCEL).
Which stock has performed better over the past year, JSPR or NCEL?
JSPR returned -76.67% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are Jasper Therapeutics and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.